Skip to main content

Advertisement

Table 3 Results of Cox regression analyses for clinicopathological factors and CXCL16 in stromal cells (model 1) and co-expression of CXCL16 in cancer and stromal cells (model 2*)

From: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival

Factor HR CI 95 % P
Tumor stage    <0.001
T1 1.00   
T2 1.60 (0.97–2.64) 0.065
T3 3.80 (2.13–6.77) <0.001
Nodal stage    <0.001
N0 1.00   
N1 2.01 (1.30–3.11) 0.002
N2 3.08 (1.74–5.44) <0.001
Differentiation    0.009
Well 1.00   
Poor 1.17 (1.12–3.85) 0.020
Moderate 2.08 (0.63–2.20) 0.618
Performance status    0.040
0 1.00   
1 1.52 (1.02–2.26) 0.040
2 2.15 (0.94–4.91) 0.069
Vascular infiltration    
No 1.00   
Yes 1.70 (1.01–2.87) 0.046
Histology    <0.001
Squamous carcinoma 1.00   
Adenocarcinoma 2.23 (1.48–3.35) <0.001
Large cell carcinoma 0.80 (0.39–1.66) 0.555
CXC16 stromal cells    
Low 1   
High 0.55 (0.35–0.87) 0.011
CXCL16 cancer and stromal cells*    0.031
Low/Low 1.00   
Low/High + High/Low 0.57 (0.35–0.93) 0.023
Low/Low 0.42 (0.20–0.88) 0.022
  1. Overall significance as prognostic marker. HR, hazard ratio; CI 95 %, 95 % confidence interval